Kidney TransplantationPhase 2NCT00483756
Study of a JAK3 Inhibitor for the Prevention of Acute Rejection in Kidney Transplant Patients
A Phase 2 study testing Cyclosporine and CP-690,550 in people with Kidney Transplantation, run by Pfizer at 69 sites in 15 countries.
Trial summary
A new immunosuppressive drug, based on the inhibition of an important enzyme in the immune system called JAK3, is being developed by Pfizer to prevent transplant rejection. In this research study, a JAK3 inhibitor or cyclosporine will be given to new kidney transplant patients for 12 months. Read more about this study
- Who is it for?
- Ages 18 to 70 years
- Conditions the study is for
- Kidney Transplantation
- What is being tested?
- Cyclosporine and CP-690,550
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 338 participants
- Where
- 69 sitesin 15 countries
- Study dates
- Aug 2007to Apr 2010
- Phase
- Phase 2
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 70 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Recipient of a first-time kidney transplant
- Between the ages of 18 and 70 years, inclusive
Who cannot join
- Recipient of any non-kidney transplant
Trial locations and contacts
69 sites in 15 countries.
69 sites in 15 countries
United States37 sites
Pfizer Investigational Site
Ann Arbor, Michigan, 48109
Pfizer Investigational Site
Aurora, Colorado, 80045
Pfizer Investigational Site
Baltimore, Maryland, 21201
Pfizer Investigational Site
Boston, Massachusetts, 02215
Pfizer Investigational Site
Chapel Hill, North Carolina, 27514
Pfizer Investigational Site
Chapel Hill, North Carolina, 27599-7155
Pfizer Investigational Site
Chapel Hill, North Carolina, 27599-7211
Pfizer Investigational Site
Chapel Hill, North Carolina, 27599-7360
Pfizer Investigational Site
Charleston, South Carolina, 29425
Pfizer Investigational Site
Chicago, Illinois, 60611
Pfizer Investigational Site
Chicago, Illinois, 60637
Pfizer Investigational Site
Dallas, Texas, 75204
Pfizer Investigational Site
Dallas, Texas, 75246
Pfizer Investigational Site
Detroit, Michigan, 48202
Pfizer Investigational Site
Fort Worth, Texas, 76104
Pfizer Investigational Site
Gainesville, Florida, 32610
Pfizer Investigational Site
Gainsville, Florida, 32610
Pfizer Investigational Site
Little Rock, Arkansas, 72205
Pfizer Investigational Site
Livingston, New Jersey, 07039
Pfizer Investigational Site
Los Angeles, California, 90048
Pfizer Investigational Site
Los Angeles, California, 90095
Pfizer Investigational Site
New Haven, Connecticut, 06504
Pfizer Investigational Site
New Haven, Connecticut, 06510
Pfizer Investigational Site
New York, New York, 10029
Pfizer Investigational Site
Palo Alto, California, 94304
Pfizer Investigational Site
Philadelphia, Pennsylvania, 19102
Pfizer Investigational Site
Portland, Oregon, 97239
Pfizer Investigational Site
Rochester, Minnesota, 55905
Pfizer Investigational Site
San Diego, California, 92123
Pfizer Investigational Site
San Francisco, California, 94115
Pfizer Investigational Site
San Francisco, California, 94143
Pfizer Investigational Site
Springfield, Massachusetts, 01107
Pfizer Investigational Site
Springfield, Massachusetts, 01199
Pfizer Investigational Site
St Louis, Missouri, 63110
Pfizer Investigational Site
Stanford, California, 94305
Pfizer Investigational Site
Tampa, Florida, 33606
Pfizer Investigational Site
Valhalla, New York, 10595
Australia6 sites
Pfizer Investigational Site
Adelaide, South Australia, 5000
Pfizer Investigational Site
Camperdown, New South Wales, 2050
Pfizer Investigational Site
Clayton, Victoria, 3168
Pfizer Investigational Site
Parkville, Victoria, 3050
Pfizer Investigational Site
Westmead, New South Wales, 2145
Pfizer Investigational Site
Woodville, South Australia, 5011
France4 sites
Pfizer Investigational Site
Nantes, 44093
Pfizer Investigational Site
Paris, 75743
Pfizer Investigational Site
Toulouse, 31059
Pfizer Investigational Site
Vandœuvre-lès-Nancy, 54500
Brazil3 sites
Pfizer Investigational Site
Porto Alegre, Rio Grande do Sul, 90020-090
Pfizer Investigational Site
São Paulo, São Paulo, 04038-002
Pfizer Investigational Site
São Paulo, São Paulo, 04039-050
South Korea3 sites
Pfizer Investigational Site
Seoul, 110-744
Pfizer Investigational Site
Seoul, 120-752
Pfizer Investigational Site
Seoul, 138-736
Belgium2 sites
Pfizer Investigational Site
Anderlecht, 1070
Pfizer Investigational Site
Leuven, 3000
Germany2 sites
Pfizer Investigational Site
Berlin, 10117
Pfizer Investigational Site
Hamburg, 20246
Italy2 sites
Pfizer Investigational Site
Bologna, 40138
Pfizer Investigational Site
Roma, 00168
Poland2 sites
Pfizer Investigational Site
Warsaw, 02-006
Pfizer Investigational Site
Wroclaw, 50-417
Portugal2 sites
Pfizer Investigational Site
Coimbra, 3000-075
Pfizer Investigational Site
Lisbon, 1069-166
Spain2 sites
Pfizer Investigational Site
Barcelona, Barcelona, 08036
Pfizer Investigational Site
L'Hospitalet de Llobregat, Barcelona, 08907
About this study
Official title: A Phase 2 Randomized, Multicenter, Active Comparator-Controlled Trial to Evaluate the Safety and Efficacy of Co-administration of CP-690,550 and Mycophenolate Mofetil / Mycophenolate Sodium in De Novo Renal Allograft Recipients
A new immunosuppressive drug, based on the inhibition of an important enzyme in the immune system called JAK3, is being developed by Pfizer to prevent transplant rejection. In this research study, a JAK3 inhibitor or cyclosporine will be given to new kidney transplant patients for 12 months. Patients will be assigned to one of three treatment groups after receiving a kidney transplant. Two of the treatment groups will receive 2 different dosing regimens of the JAK3 inhibitor that will be taken by mouth. The third treatment group will be a standard-of-care control arm. Patients will continue to take the assigned study medication for 12 months as well as other standard transplant medications such as prednisone.
- Conditions
- Kidney Transplantation
- Being tested
- Cyclosporine, CP-690,550
- Keywords
- Immunosuppression, JAK3 inhibitor, kidney transplantation.
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
CyclosporineDrug
Standard of care
CP-690,550Drug
CP-690,550 15 mg BID for Months 1-6, then 10 mg BID for Months 7-12
CP-690,550Drug
CP-690,550 15 mg BID for Months 1-3, then 10 mg BID for Months 4-12
| Study group | Role | What they receive |
|---|---|---|
| 1 | Active comparator | Treatment Arm 1 will also receive standard of care medications Receives: Drug: Cyclosporine |
| 2 | Experimental | Treatment Arm 2 will also receive standard of care medications Receives: Drug: CP-690,550 |
| 3 | Experimental | Treatment Arm 3 will also receive standard of care medications Receives: Drug: CP-690,550 |
What is being measured
The primary outcome is the main question the study is designed to answer.
Number of Participants With First Clinical Biopsy Proven Acute Rejection (BPAR) Episode 6 Months Post-Transplant
Clinical BPAR was a BPAR (category acute rejection as interpreted by the central blinded pathologist according to the Banff 97 working classification) associated with an increase in serum creatinine of >= 0.3 milligram per deciliter (mg/dL) and >=20 percent (%) from pre-rejection baseline. The increase in serum creatinine was assessed based on the comparison of baseline and the highest serum creatinine recorded within 24 hours (hrs) of the time of biopsy.
Measured: Baseline up to Month 6
Glomerular Filtration Rate (GFR) at Month 12
GFR: an index of kidney function. GFR described the flow rate of filtered fluid through the kidney. GFR was calculated using iohexol serum clearance. For determination of iohexol serum clearance, iohexol was administered as an intravenous bolus over 5 minutes immediately after morning dosing of CP-690,550 or CsA on day of GFR evaluation. A normal GFR is greater than (>) 90 milliliter per minute (mL/min), although children and older people usually have a lower GFR. Lower values indicated poor kidney function. A GFR less than (<) 15 mL/min indicated kidney failure.
Measured: 2, 3, 4, and 5 hrs post iohexol intravenous bolus at Month 12
Secondary outcomes (18)
Glomerular Filtration Rate (GFR) at Month 6
GFR: an index of kidney function. GFR described the flow rate of filtered fluid through the kidney. GFR was calculated using iohexol serum clearance. For determination of iohexol serum clearance, iohexol was administered as an intravenous bolus over 5 minutes immediately after morning dosing of CP-690,550 or CsA on day of GFR evaluation. A normal GFR is >90 mL/min, although children and older people usually have a lower GFR. Lower values indicated poor kidney function. A GFR <15 mL/min indicated kidney failure.
Measured: 2, 3, 4, and 5 hrs post iohexol intravenous bolus at Month 6
Number of Participants With Progression of Chronic Allograft Lesions at Month 12
Progression of chronic allograft lesions was defined as an increase in the Banff chronicity score (Banff-CS) in biopsy from the implantation (baseline) biopsy in a given participant. Banff-CS was the sum of the Banff scores for the 4 chronic basic lesions (allograft glomerulopathy [cg] + interstitial fibrosis [ci] + tubular atrophy [ct] + vascular intimal thickening [cv]).The Banff-CS ranged from 0-12, higher score indicated greater lesions and Month 12 Banff-CS greater than the implantation biopsy score indicated progression of lesions.
Measured: Month 12
Number of Participants With First Clinical Biopsy Proven Acute Rejection (BPAR) 12 Months Post Transplant
Clinical BPAR was a BPAR (category acute rejection as interpreted by the central blinded pathologist according to the Banff 97 working classification) associated with an increase in serum creatinine of >= 0.3 mg/dL and >=20% from pre-rejection baseline. The increase in serum creatinine was assessed based on the comparison of baseline and the highest serum creatinine recorded within 24 hrs of the time of biopsy.
Measured: Baseline up to Month 12
Number of Participants With Treated Clinical Acute Rejection
Treated clinical acute rejection was defined as an acute rejection episode that was diagnosed based on local biopsy readout and received anti-rejection treatment.
Measured: Month 6, 12
Number of Participants With Combined Banff Rejection Categories (Categories 2, 3, and 4)
Banff 97: standard classification for scoring and classifying rejection of kidney transplant biopsies in 6 diagnostic categories: normal, antibody-mediated rejection, borderline changes: 'suspicious' for acute cellular rejection, acute/active cellular rejection, chronic/sclerosing allograft nephropathy, and other. Combined Banff rejection calculated from categories of antibody-mediated rejection (Category 2) plus borderline changes (Category 3) plus acute rejection (Category 4), as interpreted by the central pathologist.
Measured: Month 6, 12
Number of Participants With Graft Loss
Graft loss was defined as graft nephrectomy, participant death, re-transplantation, or return to dialysis for >=6 consecutive weeks.
Measured: Month 6, 12
Number of Participants With Efficacy Failure
Efficacy failure was the first occurrence of clinical BPAR diagnosed by the central pathologist or graft loss including participant death.
Measured: Month 6, 12
Number of Participants Who Died
Measured: Month 6, 12
Lymphocyte Subset
The absolute cell counts of cluster of differentiation 3 (CD3): T-lymphocytes, cluster of differentiation 19 (CD19): B-lymphocytes, and cluster of differentiation 56 (CD56): assumed natural killer cells, were determined using flow cytometry.
Measured: Month 1, 3, 6, 12
Population Pharmacokinetics (PK)
Data for this Outcome Measure are not reported here because the analysis population includes participants who were not enrolled in this study. ClinicalTrials.gov is designed for reporting results from only those participants who were enrolled in the study and described in the Participant Flow and Baseline Characteristics modules.
Measured: Pre-dose-2(P-2), Pre-dose(P), 0.5,1,2 hr post-dose(PD) on Day14, Month(M) 3; P,1,2 hr PD on M1; P, 0.5, 2, 4 hr PD on M6; P-2, P, 0.5 hr PD on M9, M12 as per randomization in CP-690,550 treated; P on M3 and P, 2, 4 hr PD on M6 in CsA treated participants
Glomerular Filtration Rate (GFR) by The Nankivell Equation
GFR: an index of kidney function. GFR described the flow rate of filtered fluid through the kidney. GFR was measured directly or estimated using established formulas. GFR was calculated was estimated by creatinine clearance (CLcr) using Nankivell equation. CLcr by Nankivell equation= (6.7 per serum creatinine) plus (0.25*body weight) minus (0.5*serum urea) minus (100 per height square) plus (35 for male/25 for female). A normal GFR is >90 mL/min, although children and older people usually have a lower GFR. Lower values indicated poor kidney function. A GFR <15 mL/min indicated kidney failure.
Measured: Month 1, 3, 6, 9, 12
Glomerular Filtration Rate (GFR) by The Cockcroft-Gault Equation
GFR: an index of kidney function. GFR described the flow rate of filtered fluid through the kidney. GFR was measured directly or estimated using established formulas. GFR was calculated using Cockcroft-Gault equation. GFR by Cockcroft-Gault equation= body weight*(140 minus age in years) divided by (72*serum creatinine). For females value obtained was multiplied by 0.85. A normal GFR is >90 mL/min, although children and older people usually have a lower GFR. Lower values indicated poor kidney function. A GFR <15 mL/min indicated kidney failure.
Measured: Month 1, 3, 6, 9, 12
Glomerular Filtration Rate (GFR) by The Modification of Diet in Renal Disease (MDRD) Equation
GFR: an index of kidney function. GFR described the flow rate of filtered fluid through the kidney. GFR was calculated using MDRD equation. GFR by MDRD equation = 170 * (serum creatinine)^(-0.999) * (age in years)^(-0.176) * (0.762 if female) * (1.18 if black) * (blood urea nitrogen concentration)^(-0.170) * (serum albumin concentration)^(0.318).A normal GFR is >90 mL/min/1.73 square meter (m^2), although children and older people usually have a lower GFR. Lower values indicated poor kidney function. A GFR <15 mL/min/1.73 m^2 indicated kidney failure.
Measured: Month 1, 3, 6, 9, 12
Glomerular Filtration Rate (GFR) by The Abbreviated Modification of Diet in Renal Disease (MDRD) Equation
GFR: an index of kidney function. GFR described the flow rate of filtered fluid through the kidney. GFR was measured directly or estimated using established formulas. GFR was calculated using abbreviated MDRD equation. GFR by abbreviated MDRD equation= 186 * (serum creatinine)^(-1.154) * (age in years)^(-0.203) * (0.742 if female) * (1.210 if black). A normal GFR is >90 mL/min/1.73 m^2, although children and older people usually have a lower GFR. Lower values indicated poor kidney function. A GFR <15 mL/min/1.73 m^2 indicated kidney failure.
Measured: Month 1, 3, 6, 9, 12
Number of Participants With Clinically Significant Infections
Clinically significant infection was defined as the presence of documented infection confirmed by culture, biopsy, genomic, or serologic findings post-randomization and requiring hospitalization or parenteral anti-infective treatment, or otherwise deemed significant by the investigator.
Measured: Baseline up to Month 12
36-Item Short-Form Health Survey (SF-36)
SF-36: standardized survey evaluating 8 aspects of functional health and well-being: physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, mental health. These 8 aspects can also be summarized as physical and mental component scores. Total of 11 variables were analyzed (8 subscales,2 composite subscales and Question(Q) 2 "how would you rate your health in general now?"(range 1=better, 5=worst). The score for a section (except Q2) is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning).
Measured: Baseline, Month 6, 12
End-Stage Renal Disease Symptom Checklist Transplantation Module (ESRD-SCL)
ESRD-SCL:43-item disease specific self-administered questionnaire. Participants' rated question"At the moment,how much do you suffer?"for each item on 5 point scale,ranged (Ra) 0(not at all)to 4(extremely).Consisted of 6 subscales:cardiac and renal dysfunction;Ra 0-28,increased(In) growth of gum and hair;Ra 0-20,limited cognitive capacity;Ra 0-32,limited physical capacity;Ra 0 - 40,side effects (SEs) of corticosteroids;Ra 0-20,transplantation associated psychological distress(TAPD);Ra 0-32(higher scores=greater dysfunction for each subscale).Total score:0-172,higher scores=greater dysfunction.
Measured: Baseline, Month 6, 12
Severity of Dyspepsia Assessment (SODA)
SODA:17-item health scale, assessed participant-reported perceptions of dyspepsia;consists of 3 subscales:Pain Intensity (6-items to assess pain and intensity of abdominal [Ab] discomfort; Range (Ra):2-47, higher score= greater pain and Ab discomfort), Non-Pain Symptoms (7-items to assess severity and impact of non-pain symptoms:burping/belching,heartburn,bloating,flatulence,sour taste,nausea,and bad breath; Ra:7-35,higher scores = increased symptom severity and influence), and Satisfaction (4-items to assess degree of satisfaction with Ab discomfort; Ra:2-23,higher scores= more satisfaction).
Measured: Baseline, Month 6, 12
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted7 Jun 2007 (estimated)
- Study startAug 2007
- Primary completionFeb 2010
- Study completionApr 2010
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Other trials for Kidney TransplantationStudies of the same condition, open and under way.
- More trials run by PfizerThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 338 participants (actual)
Sponsor and investigators
- Lead sponsor
- Pfizer
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Pfizer CT.gov Call Center, Study director, Pfizer
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00483756
- Sponsor's protocol ID
- A3921030
- Status last verified
- Feb 2013
- First submitted
- 6 Jun 2007
- Last updated
- 14 Mar 2013
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 14 Mar 2013. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Phase 2 Randomized, Multicenter, Active Comparator-Controlled Trial to Evaluate the Safety and Efficacy of Co-administration of CP-690,550 and Mycophenolate Mofetil / Mycophenolate Sodium in De Novo Renal Allograft Recipients
- ClinicalTrials.gov ID
- NCT00483756
- Acronym / sponsor ID
- A3921030
- Conditions
- Kidney Transplantation
- Keywords
- Immunosuppression, JAK3 inhibitor, kidney transplantation.
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 338 participants (actual)
- Lead sponsor
- PfizerIndustry (pharma, biotech, devices)
- Study start
- Aug 2007
- Primary completion
- Feb 2010 (actual)
- Study completion
- Apr 2010 (actual)
- First posted
- 7 Jun 2007 (estimated)
- Results
- Posted 14 Mar 2013
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
A new immunosuppressive drug, based on the inhibition of an important enzyme in the immune system called JAK3, is being developed by Pfizer to prevent transplant rejection. In this research study, a JAK3 inhibitor or cyclosporine will be given to new kidney transplant patients for 12 months. Patients will be assigned to one of three treatment groups after receiving a kidney transplant. Two of the treatment groups will receive 2 different dosing regimens of the JAK3 inhibitor that will be taken by mouth. The third treatment group will be a standard-of-care control arm. Patients will continue to take the assigned study medication for 12 months as well as other standard transplant medications such as prednisone.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| 1 | Active comparator | Drug: CyclosporineTreatment Arm 1 will also receive standard of care medications |
| 2 | Experimental | Drug: CP-690,550Treatment Arm 2 will also receive standard of care medications |
| 3 | Experimental | Drug: CP-690,550Treatment Arm 3 will also receive standard of care medications |
Who may qualify
- Ages
- 18 to 70 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (2 listed)
- Recipient of a first-time kidney transplant
- Between the ages of 18 and 70 years, inclusive
Key exclusion criteria (1 listed)
- Recipient of any non-kidney transplant
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| CyclosporineStandard of care | Drug | 1 |
| CP-690,550CP-690,550 15 mg BID for Months 1-6, then 10 mg BID for Months 7-12 | Drug | 2 |
| CP-690,550CP-690,550 15 mg BID for Months 1-3, then 10 mg BID for Months 4-12 | Drug | 3 |
Primary outcome
Number of Participants With First Clinical Biopsy Proven Acute Rejection (BPAR) Episode 6 Months Post-Transplant
Time frame: Baseline up to Month 6
Clinical BPAR was a BPAR (category acute rejection as interpreted by the central blinded pathologist according to the Banff 97 working classification) associated with an increase in serum creatinine of >= 0.3 milligram per deciliter (mg/dL) and >=20 percent (%) from pre-rejection baseline. The increase in serum creatinine was assessed based on the comparison of baseline and the highest serum creatinine recorded within 24 hours (hrs) of the time of biopsy.
Glomerular Filtration Rate (GFR) at Month 12
Time frame: 2, 3, 4, and 5 hrs post iohexol intravenous bolus at Month 12
GFR: an index of kidney function. GFR described the flow rate of filtered fluid through the kidney. GFR was calculated using iohexol serum clearance. For determination of iohexol serum clearance, iohexol was administered as an intravenous bolus over 5 minutes immediately after morning dosing of CP-690,550 or CsA on day of GFR evaluation. A normal GFR is greater than (>) 90 milliliter per minute (mL/min), although children and older people usually have a lower GFR. Lower values indicated poor kidney function. A GFR less than (<) 15 mL/min indicated kidney failure.
18 secondary outcomes
Glomerular Filtration Rate (GFR) at Month 6
Time frame: 2, 3, 4, and 5 hrs post iohexol intravenous bolus at Month 6
Number of Participants With Progression of Chronic Allograft Lesions at Month 12
Time frame: Month 12
Number of Participants With First Clinical Biopsy Proven Acute Rejection (BPAR) 12 Months Post Transplant
Time frame: Baseline up to Month 12
Number of Participants With Treated Clinical Acute Rejection
Time frame: Month 6, 12
Number of Participants With Combined Banff Rejection Categories (Categories 2, 3, and 4)
Time frame: Month 6, 12
Number of Participants With Graft Loss
Time frame: Month 6, 12
Number of Participants With Efficacy Failure
Time frame: Month 6, 12
Number of Participants Who Died
Time frame: Month 6, 12
Lymphocyte Subset
Time frame: Month 1, 3, 6, 12
Population Pharmacokinetics (PK)
Time frame: Pre-dose-2(P-2), Pre-dose(P), 0.5,1,2 hr post-dose(PD) on Day14, Month(M) 3; P,1,2 hr PD on M1; P, 0.5, 2, 4 hr PD on M6; P-2, P, 0.5 hr PD on M9, M12 as per randomization in CP-690,550 treated; P on M3 and P, 2, 4 hr PD on M6 in CsA treated participants
Glomerular Filtration Rate (GFR) by The Nankivell Equation
Time frame: Month 1, 3, 6, 9, 12
Glomerular Filtration Rate (GFR) by The Cockcroft-Gault Equation
Time frame: Month 1, 3, 6, 9, 12
Glomerular Filtration Rate (GFR) by The Modification of Diet in Renal Disease (MDRD) Equation
Time frame: Month 1, 3, 6, 9, 12
Glomerular Filtration Rate (GFR) by The Abbreviated Modification of Diet in Renal Disease (MDRD) Equation
Time frame: Month 1, 3, 6, 9, 12
Number of Participants With Clinically Significant Infections
Time frame: Baseline up to Month 12
36-Item Short-Form Health Survey (SF-36)
Time frame: Baseline, Month 6, 12
End-Stage Renal Disease Symptom Checklist Transplantation Module (ESRD-SCL)
Time frame: Baseline, Month 6, 12
Severity of Dyspepsia Assessment (SODA)
Time frame: Baseline, Month 6, 12
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 14 Mar 2013.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- To obtain contact information for a study center near you, click here.Link provided by the sponsor.
Related trials for Kidney Transplantation
Enrolling by invitation
Online Exercise Program for Transplant Patients: A Pilot Study
Kidney Transplantation, Physical Function
RecruitingPhase 2
A Study of Mezagitamab in Adults With Late Antibody-Mediated Rejection (AMR) After a Kidney Transplant
Antibody-Mediated Rejection (AMR)
Not yet recruiting
Hypothermic Kidney Machine Perfusion With Omnisol
End Stage Renal Disease (ESRD), Kidney Transplant
Not yet recruitingEarly Phase 1
Biomarker-Guided Mycophenolate Mofetil Elimination in Low-Risk Older Adult Kidney Transplant Recipients
Kidney Transplant Recipient
Recruiting
Non-Invasive Monitoring of Pediatric Kidney Transplant Recipients and Immunosuppression Personalization: an Open-labeled Multicenter Randomized Controlled Study
Pediatric Kidney Disease, Transplant;Failure,Kidney
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Pfizer CT.gov Call Center study director
Pfizer
69 sites in 15 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing Cyclosporine and CP-690,550 in people with Kidney Transplantation, run by Pfizer at 69 sites in 15 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 14 Mar 2013. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 69 sites in United States, Australia, France, Brazil, South Korea and 10 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 14 Mar 2013). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Number of Participants With First Clinical Biopsy Proven Acute Rejection (BPAR) Episode 6 Months Post-Transplant (time frame: Baseline up to Month 6). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Mar 2013.